7 oktober 2021: Bron CNN o.a.

Gisteren zijn nog twee grote studies gepubliceerd die aantonen dat de bescherming door vaccins snel terugloopt na de tweede injectie. CNN heeft daar een artikel over  Studies confirm waning immunity from Pfizer's Covid-19 vaccine

Het gaat om deze twee studies: 

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

En deze Israelische studie: 

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Opvallend dat in beide studies gevonden is dat bij oudere mensen de bescherming sneller terugloopt: Zes maanden na ontvangst van de tweede dosis van het BNT162b2-vaccin was de humorale respons aanzienlijk afgenomen, vooral bij mannen, bij personen van 65 jaar of ouder en bij personen met immunosuppressie.

5 oktober 2021: Bron The Lancet

Uit een retrospectieve studie onder 5 miljoen Amerikaanse mensen ouder dan 12 jaar die verzekerd zijn bij de Health-care organisation Kaiser Permanente Southern California blijkt dat de bescherming van het Biontech/Pfizer vaccin tegen het coronavirus - Covid-19 al na 1 maand na de tweede prik terugloopt in het geven van bescherming om opnieuw besmet te worden. Op het meetpunt van 6e maand blijkt dat de bescherming om opnieuw besmet te kunnen raken teruggelopen is tot 47 procent.

Wel schrijven de onderzoekers dat de bescherming tegen ernstig ziek worden en/of ziekenhuisopname hoog blijft. Circa 90 procent. Maar daar kunnen wel vraagtekens bij gesteld worden want de gemiddelde leeftijd van alle deelnemers was 45 jaar. Bovendien in Amerika zijn de arme en veelal latino's en zwarte mensen niet verzekerd. En juist onder die bevolkingsgroepen is de natuurlijke immuniteit vaak slecht door hun voedingspatroon en leefstijl. En dus ook kwetsbaarder voor het coronavirus - Covid-19. En als je in het RIVM dashboard kijkt zie je toch ook dat er relatief weinig gezonde mensen onder de 45 jaar in het ziekenhuis terecht komen door een besmetting met het coronavirus - Covid-19. De 90 procent effectiviteit moet dus in dat licht gezien genuanceerd worden.

Uit het abstract vertaald:

Tussen 14 december 2020 en 8 augustus 2021, werden 4 920 549 personen beoordeeld op geschiktheid, en hebben we 3 436 957 (mediane leeftijd 45 jaar [IQR 29–61]; 1 799 395 [52·4%] vrouw en 1 637-394 [47,6%] man) in deze studie analyse meegenomen.
  • Voor volledig gevaccineerde personen was de effectiviteit tegen SARS-CoV-2-infecties 73% (95% BI 72-74) en tegen COVID-19-gerelateerde ziekenhuisopnames 90% (89-92).
  • De effectiviteit tegen infecties nam af van 88% (95% BI 86-89) tijdens de eerste maand na volledige vaccinatie tot 47% (43-51) na 5 maanden.
  • Van de infecties op basis van sequentie was de werkzaamheid van het vaccin tegen infecties van de delta-variant hoog tijdens de eerste maand na volledige vaccinatie (93% [95% BI 85-97]), maar daalde na 4 maanden tot 53% [39-65].
  • De effectiviteit tegen andere (niet-delta) varianten was de eerste maand na volledige vaccinatie ook hoog met 97% (95% BI 95-99), maar nam af tot 67% (45-80) na 4-5 maanden. De werkzaamheid van het vaccin tegen ziekenhuisopnames voor infecties met de delta-variant was voor alle leeftijden over het algemeen hoog (93% [95% BI 84–96]) tot 6 maanden.

Voor karakteristieken van de deelnemende mensen en indeling in leeftijdsgroepen zie deze table

In het studierapport gepubliceerd in The Lancet staan heel veel meer details en grafieken. Klik op de titel van het abstract voor het studierapport dat gratis is in te zien of te downloaden.

The Lancet: Published:October 04, 2021DOI:https://doi.org/10.1016/S0140-6736(21)02183-8

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Published:October 04, 2021DOI:https://doi.org/10.1016/S0140-6736(21)02183-8

Summary

Background

Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections. We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer–BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system.

Methods

In this retrospective cohort study, we analysed electronic health records of individuals (≥12 years) who were members of the health-care organisation Kaiser Permanente Southern California (CA, USA), to assess BNT162b2 vaccine effectiveness against SARS-CoV-2 infections and COVID-19-related hospital admissions for up to 6 months. Participants were required to have 1 year or more previous membership of the organisation. Outcomes comprised SARS-CoV-2 PCR-positive tests and COVID-19-related hospital admissions. Effectiveness calculations were based on hazard ratios from adjusted Cox models. This study was registered with ClinicalTrials.govNCT04848584.

Findings

Between Dec 14, 2020, and Aug 8, 2021, of 4 920 549 individuals assessed for eligibility, we included 3 436 957 (median age 45 years [IQR 29–61]; 1 799 395 [52·4%] female and 1 637 394 [47·6%] male). For fully vaccinated individuals, effectiveness against SARS-CoV-2 infections was 73% (95% CI 72–74) and against COVID-19-related hospital admissions was 90% (89–92). Effectiveness against infections declined from 88% (95% CI 86–89) during the first month after full vaccination to 47% (43–51) after 5 months. Among sequenced infections, vaccine effectiveness against infections of the delta variant was high during the first month after full vaccination (93% [95% CI 85–97]) but declined to 53% [39–65] after 4 months. Effectiveness against other (non-delta) variants the first month after full vaccination was also high at 97% (95% CI 95–99), but waned to 67% (45–80) at 4–5 months. Vaccine effectiveness against hospital admissions for infections with the delta variant for all ages was high overall (93% [95% CI 84–96]) up to 6 months.

Interpretation

Our results provide support for high effectiveness of BNT162b2 against hospital admissions up until around 6 months after being fully vaccinated, even in the face of widespread dissemination of the delta variant. Reduction in vaccine effectiveness against SARS-CoV-2 infections over time is probably primarily due to waning immunity with time rather than the delta variant escaping vaccine protection.

Funding

Pfizer.

References

  1. 1.
    • Polack FP 
    • Thomas SJ 
    • Kitchin N 
    • et al.
    Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.
    N Engl J Med. 2020; 383: 2603-2615
  2. 2.
    • Dagan N 
    • Barda N 
    • Kepten E 
    • et al.
    BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting.
    N Engl J Med. 2021; 384: 1412-1423
  3. 3.
    • Haas EJ 
    • Angulo FJ 
    • McLaughlin JM 
    • et al.
    Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Lancet. 2021; 397: 1819-1829
  4. 4.
    • Haas EJ 
    • McLaughlin JM 
    • Khan F 
    • et al.
    Infections, hospitalizations, and deaths averted via direct effects of the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in a nationwide vaccination campaign, Israel.
    Lancet Infect Dis. 2021; (published online Sept 22.)
  5. 5.
    • Britton A 
    • Jacobs Slifka KM 
    • Edens C 
    • et al.
    Effectiveness of the Pfizer–BioNTech COVID-19 vaccine among residents of two skilled nursing facilities experiencing COVID-19 outbreaks—Connecticut, December 2020–February 2021.
    MMWR Morb Mortal Wkly Rep. 2021; 70: 396-401
  6. 6.
    • Thompson MG 
    • Burgess JL 
    • Naleway AL 
    • et al.
    Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020–March 2021.
    MMWR Morb Mortal Wkly Rep. 2021; 70: 495-500
  7. 7.
    • Pilishvili T 
    • Fleming-Dutra KE 
    • Farrar JL 
    • et al.
    Interim estimates of vaccine effectiveness of Pfizer–BioNTech and Moderna COVID-19 vaccines among health care personnel—33 US sites, January-March 2021.
    MMWR Morb Mortal Wkly Rep. 2021; 70: 753-758
  8. 8.
    • Tenforde MW 
    • Olson SM 
    • Self WH 
    • et al.
    Effectiveness of Pfizer–BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ≥65 years—United States, January–March 2021.
    MMWR Morb Mortal Wkly Rep. 2021; 70: 674-679
  9. 9.
    • Nasreen S 
    • Chung H 
    • He S 
    • et al.
    Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada.
    medRxiv. 2021; (published online July 3.) (preprint).
  10. 10.
    • Hall VJ 
    • Foulkes S 
    • Saei A 
    • et al.
    COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.
    Lancet. 2021; 397: 1725-1735
  11. 11.
    • Lopez Bernal J 
    • Andrews N 
    • Gower C 
    • et al.
    Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant.
    N Engl J Med. 2021; 385: 585-594
  12. 12.
    • Lopez Bernal J 
    • Andrews N 
    • Gower C 
    • et al.
    Effectiveness of the Pfizer–BioNTech and Oxford–AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
    BMJ. 2021; 373n1088
  13. 13.
    • Vasileiou E 
    • Simpson CR 
    • Shi T 
    • et al.
    Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.
    Lancet. 2021; 397: 1646-1657
  14. 14.
    • Lopez Bernal J 
    • Andrews N 
    • Gower C 
    • et al.
    Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant.
    N Engl J Med. 2021; 385: 585-594
  15. 15.
    • Sheikh A 
    • McMenamin J 
    • Taylor B 
    • Robertson C
    SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
    Lancet. 2021; 397: 2461-2462
  16. 16.
    • Stowe J 
    • Andrews N 
    • Gower C 
    • et al.
    Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. Public Health England.
  17. 17.
    • Abu-Raddad LJ 
    • Chemaitelly H 
    • Butt AA
    Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants.
    N Engl J Med. 2021; 385: 187-189
  18. 18.
    • Chemaitelly H 
    • Yassine HM 
    • Benslimane FM 
    • et al.
    mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.
    Nat Med. 2021; 27: 1614-1621
  19. 19.
    • Liu J 
    • Liu Y 
    • Xia H 
    • et al.
    BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
    Nature. 2021; 596: 273-275
  20. 20.
    • Liu Y 
    • Liu J 
    • Xia H 
    • et al.
    Neutralizing activity of BNT162b2-elicited serum.
    N Engl J Med. 2021; 384: 1466-1468
  21. 21.
    • Liu Y 
    • Liu J 
    • Xia H 
    • et al.
    BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants.
    N Engl J Med. 2021; 385: 472-474
  22. 22.
    • Singer SR 
    • Angulo FJ 
    • Swerdlow D 
    • et al.
    Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant beta (B.1.351) among persons identified through contact tracing in Israel.
    SSRN, 2021 (published online Aug 13.) (preprint).
  23. 23.
    • Tang P 
    • Hasan MR 
    • Chemaitelly H 
    • et al.
    BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar.
    medRxiv. 2021; (puyblished online Aug 11.) (preprint).
  24. 24.
    • Tenforde MW 
    • Self WH 
    • Naioti EA 
    • et al.
    Sustained effectiveness of Pfizer–BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults - United States, March–July 2021.
    MMWR Morb Mortal Wkly Rep. 2021; 70: 1156-1162
  25. 25.
    • Committee IMoHC-VCE
    Vaccine effectiveness data on a cohort of persons vaccinated by 31-Jan-2021 with two doses. Presented at Israel Ministry of Health COVID-19 Vaccines Campaign Effectiveness Committee Meeting on 20-Jul-2021.
  26. 26.
    • Nanduri SA 
    • Pilishvili T 
    • Derado G 
    • et al.
    Effectiveness of Pfizer–BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (delta) variant—National Healthcare Safety Network, March 1–August 1, 2021.
    MMWR Morb Mortal Wkly Rep. 2021; 70: 1163-1166
  27. 27.
    • Rosenberg ES 
    • Holtgrave DR 
    • Dorabawila V 
    • et al.
    New COVID-19 cases and hospitalizations among adults, by vaccination status—New York, May 3–July 25, 2021.
    MMWR Morb Mortal Wkly Rep. 2021; 70: 1150-1155
  28. 28.
    • Thomas SJ 
    • Moreira ED 
    • Kitchin N 
    • et al.
    Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.
    medRxiv. 2021; (published online July 28.) (preprint).
  29. 29.
    • Koebnick C 
    • Langer-Gould AM 
    • Gould MK 
    • et al.
    Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data.
    Perm J. 2012; 16: 37-41
  30. 30.
    • Messer LC 
    • Laraia BA 
    • Kaufman JS 
    • et al.
    The development of a standardized neighborhood deprivation index.
    J Urban Health. 2006; 83: 1041-1062
  31. 31.
    • Israel Ministry of Health Epidemiology Division
    COVID-19 Weekly Data Update, 11-Aug-2021.
  32. 32.
    • Parry H 
    • Bruton R 
    • Tut G 
    • et al.
    Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5–6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis.
    Lancet Healthy Longev. 2021; 2: e554-e560
  33. 33.
    • Parry H 
    • Bruton R 
    • Stephens C 
    • et al.
    Extended interval BNT162b2 vaccination enhances peak antibody generation in older people.
    medRxiv. 2021; (published online May 17.) (preprint).
  34. 34.
    • Pfizer–BioNTech
    Pfizer and BioNTech provide update on booster program in light of the delta-variant New York and Mainz, Germany.
  35. 35.
    • Pfizer
    Pfizer second quarter 2021 earning teleconference.
  36. 36.
    • Khoury DS 
    • Cromer D 
    • Reynaldi A 
    • et al.
    Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
    Nat Med. 2021; 27: 1205-1211
  37. 37.
    • Callow KA 
    • Parry HF 
    • Sergeant M 
    • Tyrrell DA
    The time course of the immune response to experimental coronavirus infection of man.
    Epidemiol Infect. 1990; 105: 435-446
  38. 38.
    • Reuters
    Update 1-Third Pfizer dose 86% effective in over 60s, Israeli HMO says.
    https://www.reuters.com/article/health-coronavirus-israel-vaccine-idCNL1N2PP0XD
    Date: August 18, 2021
    Date accessed: August 20, 2021
  39. 39.
    • Spiro A
    COVID booster shots raise protection against severe illness to 97%. The Times of Israel.
  40. 40.
    • WHO
    Interim statement on COVID-19 vaccine booster doses 2021.
    World Health Organization, Geneva2021

Figures

  • Figure thumbnail gr1
    Figure 1Distribution of variants from January to July, 2021
  • Figure thumbnail gr2
    Figure 2Adjusted estimated vaccine effectiveness against SARS-CoV-2 infection and hospital admissions
  • Figure thumbnail gr3
    Figure 3Adjusted estimated vaccine effectiveness against SARS-CoV-2 infection by variant

Tables

Related Hub


Plaats een reactie ...

1 Reactie op "Bescherming tegen het coronavirus van het Pfizervaccin wordt na enkele maanden al minder. Na 5 maanden is slechts nog 47 procent beschermd"

  • e.valstar :
    Onjuiste uitleg :andere literatuur met betere statistiek laat een vermindering van 5-10% zien. Grafiek B die het meest objectief is laat dat ook zien. Feit is dat als men eenmaal ziek wordt men wel eerder in het ziekenhuis komt, maar de preventie tegen het krijgen van de ziekte neemt nauwelijks af. Eerst goed nadenken zou ik zeggen.

Gerelateerde artikelen
 

Gerelateerde artikelen

Dr. Sabine Hazan mocht eindelijk >> Booster vaccinaties lijken >> Maurice de Hond geeft commentaar >> Opsluiting van kwetsbare mensen >> mRNA vaccinatie tegen coronavirus >> Vitamine-C infusen met hoge >> Hydroxychloroquine plus azithromycine >> Oversterfte in Nederland en >> Oversterfte in Duitsland is >> Duitse gezondheidswerkers >>